Investing.com report covering CryoPort Inc. (CYRX) market action, institutional positioning, and fundamental catalysts.
Why CYRX Stock dropped -5.47% Today — RQD Quant Desk Flash
CryoPort Inc. (CYRX) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is CYRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, CryoPort Inc. (NASDAQ: CYRX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $17.29 (-5.47% 1D, market cap $926.4M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 17/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 7/20. Across 1016 tracked Health Care issuers, CYRX ranks #457 in composite RQD confidence.
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does CYRX compare to ANRO and ORIC in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CYRX carries a Roarable D- (43/100 RQD), trailing P/E of 11.8x, gross margin of 47.1%, and ROIC of -11.5%. By comparison, ANRO (Alto Neuroscience Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $921.0M) and ORIC (Oric Pharmaceuticals Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -33.4%, cap $931.8M). Among the 5-stock peer group, CYRX leads on earnings multiple (11.8x) while CYRX leads on capital efficiency (-11.5% ROIC).
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for CYRX?
▼
Per CYRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001124524), CryoPort Inc. generated $176.2M in revenue (+12.4% YoY), $78.3M in net income, and -$25.0M in free cash flow against $765.0M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±8.9% realized swing band)
Altman Z-Score 1.33 (DISTRESS RISK (<1.8)) • Piotroski F-Score 5/9
Capital intensity & 0% operating margin leave 16 pts on the table
⚔️ Adversarial Opposing Case: What Could Spark a CYRX Turnaround Squeeze
While CYRX currently carries a cautious 43/100 (D-) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Big institutional funds and options desks are actively positioning on the bullish side.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($16.98) and Max Pain ($18.15) forces dealer call-delta covering toward $19.82.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.36% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Why CYRX Stock dropped -5.47% Today — RQD Quant Desk Flash
CryoPort Inc. (CYRX) dropped -5.47% to $17.29, trading at 86% of its 52-week range ($7.61 – $18.88). Stretched risk/reward at 12x P/E (-12% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 86% of its 52-week range ($7.61 – $18.88) with RSI-14 at 56.6 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±8.9% around $17.29 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 47.1% gross margin and $0 annual free cash flow.
Moomoo report covering CryoPort Inc. (CYRX) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering CryoPort Inc. (CYRX) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering CryoPort Inc. (CYRX) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering CryoPort Inc. (CYRX) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering CryoPort Inc. (CYRX) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering CryoPort Inc. (CYRX) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering CryoPort Inc. (CYRX) market action, institutional positioning, and fundamental catalysts.
Conestoga Micro Cap Composite reports 3Q26 performance highlights and portfolio adjustments. Review the latest leadership and laggard insights here.
Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced that the Company will report finan
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CYRX)
- ✓Walkthrough of CYRX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
CYRX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +12.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on CYRX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for CYRX. Explore sector supply chains on /butterfly.
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CYRX)
1. Head-to-Head Health Care Peer Comparison (CYRX vs. ANRO, ORIC, AKTS, KURA)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, CryoPort Inc. (CYRX) ranks #457 by composite RQD confidence (43/100, grade D-) and #373 by equity capitalization ($926.4M). Within this direct 5-issuer industry benchmark cohort, CYRX leads on earnings valuation at 11.8x trailing P/E, while CYRX leads on capital efficiency and profitability with -11.5% ROIC and 47.1% gross margin. CYRX currently leads its immediate peer cohort in composite quantitative strength at 43/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CYRX
ACTIVE
CryoPort Inc. | D- | 43/100 | 11.8x | 47.1% | -11.5% | -5.47% | $926.4M | Benchmark Subject |
| ANRO Alto Neuroscience Inc. | D- | 35/100 | — | — | -35.0% | -3.71% | $921.0M | /anro-vs-cyrx → |
| ORIC Oric Pharmaceuticals Inc. | E | 29/100 | — | — | -33.4% | +2.78% | $931.8M | /oric-vs-cyrx → |
| AKTS Aktis Oncology Inc. | D- | 41/100 | — | — | — | -5.46% | $937.2M | /akts-vs-cyrx → |
| KURA Kura Oncology Inc. | E | 32/100 | — | — | -35.0% | -2.84% | $939.4M | /kura-vs-cyrx → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001124524In its most recent audited fiscal period (FY2025, filed 2025-12-31), CryoPort Inc. (CYRX) reported GAAP revenue of $176.2M (+12.4% vs. FY2024 revenue of $156.8M , and +4.5% cumulative change since FY2023) , GAAP net income of $78.3M, operating cash flow of -$8.6M, and free cash flow of -$25.0M (+25.5% YoY). On the balance sheet, CYRX closed FY2025 with $765.0M in total assets against $0 in total debt (Altman Z-Score: 1.33, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $176.2M | $78.3M | -$8.6M | -$25.0M | $765.0M | — |
| FY2024 (FY) | 2024-12-31 | $156.8M | -$114.8M | -$16.3M | -$33.6M | $703.5M | — |
| FY2023 (FY) | 2023-12-31 | $168.7M | -$99.6M | -$757.0K | -$757.0K | — | — |
3. CYRX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs CYRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, CryoPort Inc. (NASDAQ: CYRX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $17.29 (-5.47% 1D, market cap $926.4M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 17/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 7/20. Across 1016 tracked Health Care issuers, CYRX ranks #457 in composite RQD confidence.
How does CYRX compare to ANRO and ORIC in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CYRX carries a Roarable D- (43/100 RQD), trailing P/E of 11.8x, gross margin of 47.1%, and ROIC of -11.5%. By comparison, ANRO (Alto Neuroscience Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $921.0M) and ORIC (Oric Pharmaceuticals Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -33.4%, cap $931.8M). Among the 5-stock peer group, CYRX leads on earnings multiple (11.8x) while CYRX leads on capital efficiency (-11.5% ROIC).
What are the biggest fundamental strengths and SEC risk factors for CYRX?
Per CYRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001124524), CryoPort Inc. generated $176.2M in revenue (+12.4% YoY), $78.3M in net income, and -$25.0M in free cash flow against $765.0M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is CYRX trading relative to its 50-day, 200-day, and 52-week technical levels?
CYRX last traded at $17.29 (-5.47% on volume of 1,041,245 shares), positioning the stock +1.83% above its 50-day simple moving average ($16.98) and +29.61% above its 200-day simple moving average ($13.34). Across its 52-week range of $7.61 to $18.88, CYRX sits at the 85.9% percentile with a 14-day RSI of 56.6 (BULLISH MOMENTUM) and an implied next-earnings move of ±8.9% ($15.75 to $18.83).
CYRX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is CYRX stock moving today?
Why CYRX Stock dropped -5.47% Today — RQD Quant Desk Flash. Stretched risk/reward at 12x P/E (-12% return on capital) under elevated 10-year interest-rate pressure.
CYRX — CryoPort Inc.: What the Facts Mean to a Prospective Investor
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, CYRX scores 43 out of 100, with a letter grade of D- and a verdict label of "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:
- Fundamental Cash Engine: 1 / 20. Per the RQD rating, this is driven by ROIC of -11.5% and an FCF yield of -2.7%. This is the weakest pillar and signals that the business is not currently converting capital into positive economic returns or free cash flow. For a prospective investor, the cash engine is the core question, and today it is not supporting the valuation on a cash basis.
- Whale 13F Flow: 17 / 20. Per the RQD rating, this reflects institutional accumulation and options positioning. This is the strongest pillar and indicates that large holders are positioned constructively. The data does not itemize the holders, so the composition and size of positions cannot be verified from the source data.
- Insider Conviction: 7 / 20. Per the RQD rating, this reflects SEC Form 4 and Congressional PTR cluster flow. The weak score is consistent with the Moomoo headline in the news section referencing insider selling of US$3.4m.
- Macro Regime Fit: 8 / 20. Per the RQD rating, beta is 1.0 with sector sensitivity noted. A beta of 1.0 means the stock is expected to move roughly in line with the market, which provides neither a defensive buffer nor a high-beta amplification.
- Forensic Balance Sheet: 10 / 20. Per the RQD rating, the Altman Z-Score is 1.33, the Piotroski F-Score is 5/9, and Debt/Equity is 0.5. An Altman Z in this range is a stress signal in the source framework, so the balance sheet is a meaningful drag on the score.
Taken together, the RQD profile describes a stock with strong institutional support and a weak underlying cash and balance-sheet foundation. Upside drivers would need to come from improving operating economics, since the rating shows the fundamental engine is the largest deficit. The valuation tradeoff is that the market data shows a P/E (TTM) of 11.8 and a forward P/E of 9.9 against a negative operating margin, which means the earnings multiple is not reflecting the operating loss in a straightforward way and should be interpreted cautiously.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $176.2M | $-36.8M | $78.3M | N/A | $-25.0M | $250.5M | N/A |
| FY 2024 | $156.8M | $-121.7M | $-114.8M | N/A | $-33.6M | $34.1M | N/A |
| FY 2023 | $168.7M | $-100.5M | $-99.6M | N/A | $-0.8M | N/A | N/A |
Per the SEC financials, revenue moved from $168.7M in FY 2023 to $156.8M in FY 2024 and $176.2M in FY 2025, while operating income remained negative in all three periods. FY 2025 net income of $78.3M is positive despite a negative operating income of $-36.8M, a divergence the source data does not explain. The market data reports an operating margin of -20.9%, a gross margin of 47.1%, and a net margin of 44.4%. Per the Roarable RQD rating, ROIC is -11.5%, the Altman Z-Score is 1.33, and the Piotroski F-Score is 5/9. The reported cash balance rose to $250.5M in FY 2025 from $34.1M in FY 2024, while debt is Not available in source data for all periods, so the balance sheet posture cannot be fully characterized.
Recent Catalysts & News Wire Analysis
Per the recent news feed, the most prominent catalyst is a headline stating that BTIG raised its price target to $26 on facility expansion, flagged as a GREEN catalyst by Investing.com. Other items include a Moomoo report of US$3.4m in insider share sales, flagged YELLOW as a risk watch item for signaling hesitancy. MarketBeat reports the share price crossing above the 200-day moving average and reaching a new 52-week high, both flagged YELLOW as market-wire items. A Benzinga transcript covers the Q2 2026 earnings call, and a Simply Wall St piece references an 86% rally, flagged GREEN. The Butterfly Supply-Chain Graph reports no supply-chain links and no proprietary signals, so no butterfly-derived catalysts are available.
Open Questions
- What drove the divergence between FY 2025 net income of $78.3M and operating loss of $-36.8M, and is the net income figure driven by non-operating or one-time items?
- What is the debt level and debt structure in each period, given that debt is reported as N/A across the SEC financials?
- What are the company's product lines, customer concentration, and revenue mix, which the profile and financials do not describe?
- What is the composition and size of the institutional and options positioning behind the 17/20 whale-flow pillar, and do the holder positions persist?
- What is the status and expected timing of the facility expansion cited in the BTIG headline, and what capital is required to fund it against a $250.5M cash balance?
CYRX Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for CryoPort Inc. (CYRX) • Click "Debate This Headline" to argue it in the Roar Pit below
Investing.com report covering CryoPort Inc. (CYRX) market action, institutional positioning, and fundamental catalysts.
Moomoo report covering CryoPort Inc. (CYRX) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering CryoPort Inc. (CYRX) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering CryoPort Inc. (CYRX) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering CryoPort Inc. (CYRX) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering CryoPort Inc. (CYRX) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering CryoPort Inc. (CYRX) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering CryoPort Inc. (CYRX) market action, institutional positioning, and fundamental catalysts.
CYRX Bull vs. Bear Conversation Board — What's Your Call at $17.29?
🔥 Official Bull vs. Bear Debate: Is CYRX (D- • RQD 43/100) a Buy at $18.29?
Welcome to the CYRX (CryoPort Inc.) Roar Pit. Current RQD Composite is 43/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Pump the brakes on CYRX — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on CYRX, but look at what you are paying: 11.8x trailing P/E with 47.1% gross margins. Unless CryoPort Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
CYRX cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on CYRX, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $18.29 (52-wk range $7.61 - $18.88), any beat on forward guidance forces shorts and underweight funds to chase.